Navigation Links
The International Myeloma Foundation Reports Positive Shift In,Treatment Paradigm For Patients

-Second Closure of Multi-Center Trial in 4 Weeks Reinforces Benefits of Using REVLIMID with Low Dose Steroids in Myeloma-

NORTH HOLLYWOOD, Calif., May 15, 2007 /PRNewswire/ -- The International Myeloma Foundation (IMF) - supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians - today said that for the second time in four weeks a multi-center myeloma trial using REVLIMID(R) has demonstrated positive findings and therefore has been halted early. As a result medical experts are backing the use of new, less toxic and more tolerable treatments for multiple myeloma, the second most common of the blood cancers in the United States.

    -- In April, the Eastern Cooperative Oncology Group (ECOG) stopped the use

       of high dose dexamethasone, a steroid commonly used when treating

       patients with REVLIMID, (lenalidomide) an oral medication from Celgene.

       Based on the findings, the data safety monitoring committee recommended

       all patients in the study be moved to a regimen of REVLIMID with low-

       dose dexamethasone, which demonstrated improved survival and was better

       tolerated.

    -- Now based on these findings and early analysis of its own data the

       Southwest Oncology Group (SWOG), the largest of the NIH sponsored

       multi-center cooperative group, has brought its trial of high dose

       dexamethasone versus Revlimid plus high dose dexamethasone to an early

       close and also recommended patients be transitioned to a REVLIMID/LDD

       regimen.

    -- Based on these findings, The International Myeloma Foundation's US

       MYELOMA FORUM, a committee of the nation's leading myeloma experts, is

       considering the first large, inter-group trial for newly-diagnosed

       patients using novel agents (either REVLIMID with low-dose

       dexamethasone  or REVLIMD plus other agents such as VELCADE(R) with

       low-dose dexameth
asone) without front-line transplant.

"This is an important series of steps for myeloma patients, as we now have regimens that are more tolerable and at the same time may be more effective," said Brian G.M. Durie, M.D., chairman and co-founder of the IMF and co-chair of the SWOG myeloma committee. "Based on this new clinical evidence, we believe that regimens that include REVLIMID with low dose steroid are an important option for patients with myeloma at all stages of the disease."

Susie Novis, president and co-founder of the IMF, added, "These findings are particularly exciting because the use of low dose dexamethasone was proposed by patients themselves, showing how much can be achieved when we empower patients and listen to what they have to say. In addition, closer cooperation between the two large cooperative groups, SWOG and ECOG, will provide important benefits to patients."

Myeloma, also called multiple myeloma, is a cancer of the bone marrow that affects production of red cells, white cells and stem cells. It affects an estimated 750,000 people worldwide, and in industrialized countries it is being diagnosed in growing numbers and in increasingly younger people.

ABOUT The International Myeloma Foundation

The International Myeloma Foundation is the oldest and largest myeloma organization, reaching more than 135,000 members in 113 countries worldwide. A 501 (c) 3 non-profit organization dedicated to improving the quality of life of myeloma patients and their families, the IMF focuses on four key areas: research, education, support and advocacy. To date, the IMF has conducted more than 100 educational seminars worldwide, maintains a world-renowned hotline, and operates Bank on a Cure(R), a unique gene bank to advance myeloma research. The IMF can be reached at 818-487-7455. The global Website is http://www.myeloma.org with a companion Website in Spanish at http://www.myelomala.org.


    CONTACT:                                Media:

    International Myeloma Foundation        Stephen Gendel, BioCom Partners

    800 452-2873                            212 918-4650


CONTACT: The International Myeloma Foundation, +1-800-452-2873, or StephenGendel of BioCom Partners, +1-212-918-4650, for The International MyelomaFoundation

Web site: http://www.myeloma.org/http://www.myelomala.org/

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
7. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
9. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... 9, 2016 Research and Markets has announced ... report to their offering. ... The global travel vaccines market to grow at a ... covers the present scenario and the growth prospects of the global ... report considers the revenue generated from the sales of various vaccines ...
(Date:12/8/2016)... , Dec. 8, 2016 Australia Ophthalmic Lasers ... report, "Australia Ophthalmic Lasers Market Outlook to 2022", provides ... The report provides value, in millions of US dollars, ... segements - Excimer Lasers, Femtosecond Lasers and YAG Lasers. ... shares data for each of these market segements, and ...
(Date:12/8/2016)... KEY FINDINGS The global medical ... Various reasons for growth of the medical lifting sling ... chronic diseases, high recovery cost of injuries and government ... lifting sling refers to an assistive device that helps ... connect to the lift and hold the patient. It ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... 08, 2016 , ... Russ DiGilio , founder and ... #QuackGivesBack campaign which supported local breast cancer organizations during National Breast Cancer Awareness ... Back initiative, and we’re very pleased with the participation in every franchisee’s ...
(Date:12/8/2016)... , ... December 08, 2016 , ... CURE Media Group, ... and advocacy groups, has aligned with Upstage Lung Cancer in efforts to combat lung ... announcement, Michael J. Hennessy, Jr said, “CURE Media Group is honored to team up ...
(Date:12/8/2016)... Fla (PRWEB) , ... December 08, 2016 , ... ... smarter modes of access for customers and employees that are both engaging and ... 7 with Service Smart Technology, the software company revealed today its plans to ...
(Date:12/8/2016)... ... 08, 2016 , ... STAT courier is pleased to announce that due to ... they are expanding their presence in Dallas. One of the most exciting parts for ... jobs to the Dallas and Forth Worth market. STAT takes pride in treating their ...
(Date:12/8/2016)... ... December 08, 2016 , ... Vida Health, the ... Series B led by Canvas Ventures . Other investors include Nokia Growth Partners ... mobile platform to serve more consumers who are managing chronic conditions or ...
Breaking Medicine News(10 mins):